Abstract
Individuals of African ancestry remain largely underrepresented in genetic and proteomic studies. Here, we measure the levels of 2,873 proteins using the Olink proximity extension assay in plasma samples from 163 individuals with type 2 diabetes (T2D) or prediabetes and 362 normoglycemic controls from the Ugandan population for the first time. We identify 88 differentially expressed proteins between the two groups and 208 proteins associated with cardiometabolic traits. We link genome-wide data to protein expression levels and construct the first protein quantitative trait locus (pQTL) map in this population. We identify 399 independent associations with 346 (86.7%) cis-pQTLs and 53 (13.3%) trans-pQTLs. 16.7% of the cis-pQTLs and all of the trans-pQTLs have not been previously reported in African-ancestry individuals. Of these, 37 pQTLs have not been previously reported in any population. We find evidence for colocalization between a pQTL for SIRPA and T2D genetic risk. Mendelian randomization analysis identified 20 proteins causally associated with T2D. Our findings reveal proteins causally implicated in the pathogenesis of T2D, which may be leveraged for personalized medicine tailored to African-ancestry individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
UGR/GPC was supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, through core funding to the MRC/UVRI and LSHTM Uganda Research Unit. The 2023 Award Fellowship support of the Alexander Von Humboldt Stiftung Foundation to OS is acknowledged. SF was supported by the Wellcome Trust grant number 220740/Z/20/Z.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Uganda Virus Research Institute Research and Ethics Committee (UVRI REC #GC/127/907) and the Uganda National Council for Science and Technology (UNCST HS2527ES).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
